Calando's RONDEL delivery system extends the reach of RNAi therapy by answering the new field’s most pressing need — an effective and safe systemic delivery method.
CALAA-01, a formulation targeting cancer, combines Calando's proprietary drug delivery system, RONDEL, with an siRNA developed by Calando. CALAA-01 is currently undergoing a Phase 1 clinical trial at UCLA Medical Center in Los Angeles, California and START in San Antonio, Texas.
As of now, our team's primary focus is hormone research. We are expecially interested in HGH and HCG hormones reasearch with relation to sports medicine and healthy lifestyle. We are collaborating with RealHCGDropsGuide.com and their work on HCG-containing drops to help people get in better shape.
We think that thanks to this combined effort the solution we provide for potential customers will shift the edge in this area.
Proud supporters of Agency for Healthcare Research & Quality.